Purpose: To evaluate changes in corneal endothelial cell density over time in patients with dry eye disease (DED) and to correlate endothelial cell loss with corneal subbasal nerve density.
D
ry eye disease (DED) is the most common reason for patients to see an ophthalmic care provider and affects 5% to 35% of the population. [1] [2] [3] Although DED is traditionally considered as a disease of the tear film and ocular surface, recent studies have demonstrated more extensive involvement of the conjunctiva and cornea in these patients. Using in vivo confocal microscopy (IVCM), various conjunctival and corneal changes have previously been reported, such as increased density of conjunctival inflammatory cells, reduced density of corneal superficial epithelium, increased density of corneal basal epithelium, increased number of subbasal immune dendritic cells, decreased density of subbasal nerves, and increased number of hyperreflective activated stromal keratocytes. [4] [5] [6] Furthermore, we have recently observed that patients with moderate to severe DED have a significant reduction in central corneal endothelial cell density (CECD), which is accompanied with a decreased density of corneal subbasal nerves. 7 The cornea has the highest nerve density in the body, 8, 9 and these nerves are known to provide trophic support for the corneal epithelium. 9, 10 As a simultaneous reduction of corneal nerves and endothelial cells has been observed in many local and systemic conditions, [11] [12] [13] [14] [15] we previously suggested that these nerves may play a role in the maintenance of corneal endothelial cell function and survival. 7, 16 In this study, we have hypothesized that because of the potential supportive role of nerve-derived molecules for corneal endothelial cells, DED patients with a reduced corneal nerve density have an accelerated corneal endothelial loss, which is more than that found with normal aging. Therefore, this study was designed to evaluate corneal endothelial cell changes over time in patients with DED and to correlate these changes with corneal subbasal nerve density.
METHODS
This retrospective observational study included 40 eyes of 20 patients with DED (the DED group) and 13 eyes of 13 normal age-matched controls (the control group). To evaluate changes in densities of corneal endothelial cells and subbasal nerves over time, patients included in the DED group were those who had 2 full-thickness IVCM scans of the central cornea at least 18 months apart as their routine evaluation for DED. In all these individuals, images obtained by IVCM were used to measure CECD and subbasal nerves, as detailed below. The patients had been seen at the Cornea and Refractive Surgery Service, Massachusetts Eye and Ear Infirmary, Boston, MA. The protocol of the study was approved by the Institutional Review Board of Massachusetts Eye and Ear Infirmary, and the study was in compliance with the Health Insurance Portability and Accountability Act and in adherence to the tenets of the Declaration of Helsinki.
The DED group included patients who had typical symptoms of DED with a Schirmer test score with anesthesia ,10 mm and/or tear breakup time (TBUT) ,10 seconds. Exclusion criteria consisted of any of the following before the initial visit or during the follow-up: history of increased intraocular pressure, history of any ocular surgery, contact lens wear, history of use of any medications known to have corneal toxicity, any corneal disease including herpetic keratitis, or presence of guttae on clinical examination or IVCM scans. Patients with diabetes mellitus were excluded from this study as well.
The control group consisted of healthy individuals with normal ocular examination without any previous ocular disease or surgery. Those with endothelial guttae in IVCM, a history of contact lens wear, or those with diabetes mellitus were excluded from the control group.
All individuals had a complete ophthalmic evaluation including a detailed slit-lamp biomicroscopy with measurement of corneal fluorescein staining (Oxford scale, grades 0-5) and TBUT as well as the Schirmer test with anesthesia. Furthermore, all these individuals had full-thickness IVCM imaging of the central cornea as described below.
In Vivo Confocal Microscopy
All participants had undergone laser-scanning IVCM of the central cornea using the Heidelberg Retina Tomograph 3 with the Rostock Cornea Module (Heidelberg Engineering, Heidelberg, Germany). The microscope uses a 670-nm diode laser source and provides images from full thickness of the cornea. These images represent a coronal section of 400 · 400 mm of the cornea.
The details of IVCM imaging of the cornea have been described before. 17 Briefly, hypromellose 0.3% (GenTeal gel; Novartis Ophthalmics, East Hanover, NJ) was used to fill the disposable sterile polymethylmethacrylate cap (Tomo-cap; Heidelberg Engineering). The same gel was also used as a coupling medium between the cap and the cornea. The module was manually advanced until the gel touched the corneal surface. After visualization of the corneal epithelium, the focus was advanced to the corneal subbasal layer, stroma, and endothelium. Multiple locations in the central cornea were imaged using the Sequence Scan mode to obtain at least 1 to 2 sequence scans in each layer with each sequence consisting of 100 digital images (at least 100-200 images per layer).
Image Analysis
To measure the density of subbasal nerves, 3 representative images from various locations of the layer immediately posterior to the basal epithelial layer were selected. All visible nerve fibers in each frame were traced, and their density was calculated using NeuronJ software (http://www.imagescience. org/meijering/software/neuronj/), which is a semiautomated plugin program of ImageJ (National Institutes of Health, Bethesda, MD, http://imagej.nih.gov/ij/). 17 The nerve density of the 3 IVCM images was averaged and expressed as mm/mm 2 .
To measure CECD, 3 representative images of the corneal endothelial layer were chosen for analysis. The CECD measurement was performed using the variableframe method. 7, 18 To do this, IVCM images were exported and then analyzed using ImageJ. First, the boundary of the largest possible area in which all cell borders were clearly distinct was traced using the Polygon Selection tool of ImageJ. Second, the area of the selected part was measured in mm 2 . Third, the number of the cells in the selected area was counted using the Cell Counter plug-in of ImageJ. These were used to calculate CECD as cells/mm 2 . The mean CECD of 3 IVCM images was then calculated. All measurements in this study were performed by 2 independent, masked observers, and the average values were used for the analysis.
Statistical Analysis
SPSS for Windows version 21 (SPSS Inc, Chicago, IL) was used for statistical analysis. The lack of a normal distribution of the data was first confirmed using the Shapiro-Wilk test. To compare the age and sex between DED and control groups, the Mann-Whitney U test and x 2 test were used, respectively. To compare CECD and subbasal nerve density between DED and control groups as well as between initial and follow-up visits in the DED group, mixed model analysis was used to compensate for including both eyes of patients in the DED group. In this model, the potential confounding effect of age was also accounted for. To compare CECD and subbasal nerve density between both eyes at the initial and follow-up visits, as well as to compare the changes in CECD and subbasal nerve density over follow-up in right and left eyes separately, the Wilcoxon signed-rank test was used. Moreover, to correlate the changes of CECD over time with age and subbasal nerve density, the Spearman rank-order correlation test was performed. Twosided P # 0.05 was considered statistically significant for all comparisons.
RESULTS
This study included 40 eyes of 20 patients (15 women and 5 men) with a mean age of 60.4 6 12.3 years (range, 32-88 yrs) as the DED group and 13 eyes of 13 patients (8 women and 5 men) with a mean age of 56.8 6 4.8 years (range, 50-64 yrs) as the control group. There were no significant differences in terms of age or sex between both groups (P = 0.22 and P = 0.46, respectively). In the DED group, all patients had chronic dry eye with a mean duration of 3.8 6 3.3 years.
At the initial visit, the mean values for corneal fluorescein staining, TBUT, and Schirmer test in the DED group were 1.3 6 0.9 (range, 0-4), 4.3 6 2.3 seconds (range, 0-8 s), and 9.4 6 4.1 mm (range, 2-15 mm), respectively. The mean follow-up time in the DED group was 33.2 6 10.2 months (range, 21-57 mo). In this follow-up, patients had been treated with autologous serum drops in 15 (75%), topical antiinflammatory medications in 15 (75%), omega-3 fatty acid supplements in 14 (70%), and doxycycline or azithromycin for associated meibomian gland dysfunction in 15 (75%).
At the initial visit, central corneal subbasal nerve density was significantly lower in the DED group (17.8 6 7.5 mm/mm 2 ) than in the control group (22.8 6 3.0 mm/ mm 2 ), with P = 0.02 (Figs. 1 and 2) . CECD was 2620 6 386 cells/mm 2 and 2861 6 292 cells/mm 2 in DED and control groups, respectively, with the difference being marginally significant (P = 0.08) (Figs. 1 and 2) .
At the end of follow-up, although there was no significant change in central subbasal nerve density (16.7 6 7.2 mm/mm 2 , P = 0.53), the mean CECD significantly decreased to 2465 6 391 cells/mm 2 (P = 0.01) (Figs. 1 and  2 ). The mean corneal endothelial cell loss during the followup was 2.1 6 3.6% per year.
Corneal endothelial cell loss during follow-up showed a statistically significant negative correlation with the initial subbasal corneal nerve density (Rs = 20.55, P = 0.02) but not with the age at the initial visit (P = 0.33) or initial CECD (P = 0.82). Comparisons of CECD and subbasal nerve density in both eyes at the initial and follow-up visits have been presented in Tables 1 and 2 .
DISCUSSION
This study demonstrated reduced densities of corneal endothelium and subbasal nerves in patients with DED compared with an age-matched control group. In addition, we found that patients with DED had an accelerated corneal endothelial cell loss over time compared with physiologic aging. The cell loss was more prominent in those who initially had a lower corneal subbasal nerve density. These findings provide additional evidence of more extensive involvement of corneal structures in DED.
At the initial visit of this study, we noted a significantly lower density of corneal subbasal nerves in the central cornea of patients with DED compared with the control group, and the nerve density in the DED group did not show any significant change during the mean follow-up of 33 months. Although reduced subbasal nerve density in DED has previously been reported, [19] [20] [21] [22] its changes over time have not been evaluated before. Although the exact mechanisms of corneal nerve loss in DED are not clear, it may be speculated that the induced inflammation may be the causative factor for such nerve loss. Therefore, treatment of inflammation, as had been performed in the majority of our patients, might have prevented further loss of corneal nerves, resulting in a stable nerve density. On the other hand, most of our patients were using autologous serum eye drops, which have some nerve growth factors 23 ; this may also further increase the nerve density, 24, 25 or at least compensate for the DED-induced nerve loss.
In our study, we noted that at the initial visit, patients with DED had a lower CECD than that of the control group with the difference being marginally significant. This further confirms our previous study, which demonstrated a significantly lower CECD in patients with DED. 7 The lack of a statistically significant difference in CECD between both groups may be due to the fact that DED was less severe in the present study compared with the previous one, or alternatively, it may be due a smaller sample size in the present study.
Interestingly, repeat IVCM imaging after a mean follow-up of 33 months showed that CECD decreased significantly in our patients with DED, with a mean corneal endothelial cell loss rate of 2.1% per year. This is higher than physiologic corneal endothelial cell loss with normal aging, which has rates of 0.22% to 0.6% per year. [26] [27] [28] It is important to note that in studies on the effects of normal aging on corneal endothelial cell loss, although obvious causes of endothelial cell loss have been excluded, such as intraocular surgeries, corneal dystrophies, contact lens wear, or glaucoma, they have not excluded DED. Therefore, with excluding DED, which is more common in the elderly, 1 normal aging may be associated with less endothelial cell loss than reported before. In addition, higher standard deviations of corneal endothelial cell loss in older individuals, which have been reported before, [29] [30] [31] may partly be due to the presence of DED in only a subgroup of these cases. The mechanisms underlying this accelerated corneal endothelial cell loss in patients with DED are not clear. Accelerated endothelial cell loss compared with normal aging has previously been described in various conditions including Fuchs endothelial dystrophy, corneal infections, glaucoma, and intraocular surgeries such as cataract surgery and corneal transplantation. [32] [33] [34] [35] [36] Although accelerated corneal endothelial cell loss over time may be easily explained by direct involvement of the endothelial cells in some of these conditions, the presence of such a phenomenon after intraocular procedures is more complex. It has been shown that corneal endothelial cell loss after surgical procedures has 2 phases: a rapid early phase due to the surgical trauma and a slow chronic phase that persists for many years after surgery. 37 Although the mechanisms involved in accelerated endothelial cell loss in this slow chronic phase have not been understood, chronic subclinical inflammation due to breakdown of the blood-ocular barrier has been proposed to play a role. 37 Therefore, it may be speculated that in patients with DED, chronic inflammation involving the deep cornea and/or aqueous humor may result in an accelerated corneal endothelial cell loss. The majority of our patients had been treated with antiinflammatory medications during their follow-up in this study. Thus, the presence of the observed accelerated cell loss may implicate that the treatment of subclinical inflammation in DED was not adequate to prevent corneal endothelial cell loss, or alternatively, it may show the role of other contributing mechanisms such as corneal nerves.
Interestingly, our study demonstrated a significant correlation between initial corneal subbasal nerve density and the rate of corneal endothelial cell loss over time, with more cell loss noted in patients with low subbasal nerve density. Previously, a significantly lower corneal endothelial density compared with that of the controls has been reported in patients with neurosurgically induced neurotrophic keratitis, which showed a correlation with the duration of the neurotrophic state. 38 Moreover, in addition to DED, a reduction of density and/or function of both corneal endothelium and subbasal nerves has been reported in other ocular conditions such as diabetes, contact lens wear, and herpes simplex keratitis. [11] [12] [13] [14] [15] Thus, it may be speculated that nervederived molecules may directly or indirectly play a role in maintenance of corneal endothelial cells.
The potential effects of nerve-derived molecules on corneal endothelial cells may be expected as these cells originate from the neural crest. 39 It has been shown that these cells express muscarinic acetylcholine receptors. 40, 41 Moreover, vasoactive intestinal polypeptide (VIP), which is a neuropeptide, has been demonstrated to enhance survival of corneal endothelium. 42, 43 Therefore, the reduced number of corneal nerves in DED may be associated with decreased trophic support for corneal endothelial cells, resulting in FIGURE 2. Corneal subbasal nerves (A) and corneal endothelial cells, as their borders were marked by the variable-frame method, (B) in a normal control. A patient with DED shows reduced densities of corneal subbasal nerves (C) and corneal endothelial cells (D) compared with those of the control. After a followup of more than 3 years, there was no substantial change in corneal subbasal nerve density (E). However, CECD showed a significant reduction (F). Note that not all cases demonstrated such a dramatic decrease in endothelial cell density. It should be noted that although we observed a mean annual rate of 2.1% for corneal endothelial cell loss in patients with DED, it may be unlikely that this rate remains linear as DED is not a known cause of corneal endothelial decompensation. Thus, compensatory mechanisms, yet to be determined, probably play a role in mitigating the effect of DED on CECD. Furthermore, the DED characteristics, including its chronicity and severity, could have some effects on this cell loss.
Although we measured CECD using the variable-frame method, which has been shown to be accurate, 44 we did not evaluate the morphology of endothelial cells, interim time points, or effects of each individual treatment. Furthermore, only central CECD was measured in our study without evaluating peripheral endothelial cells. The use of different DED treatments in our patients, as usually seen in practice, also precludes us from investigating the natural course of corneal endothelial cell loss in patients with DED. The data from our retrospective study on a small sample size of patients with DED can be used as the basis for future large prospective studies to confirm corneal endothelial cell changes in this very common condition.
